UK Markets close in 3 mins

Alzamend Neuro, Inc. (ALZN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.1300-0.0700 (-3.18%)
As of 04:00PM EST. Market open.

Alzamend Neuro, Inc.

3802 Spectrum Boulevard
Suite 112C
Tampa, FL 33612
United States
844 722 6333
http://www.alzamend.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees2

Key executives

NameTitlePayExercisedYear born
Mr. Stephan JackmanCEO & Director225kN/A1976
Mr. Henry C.W. Nisser Esq.Exec. VP, Gen. Counsel & Director50kN/A1969
Mr. Kenneth S. Cragun CPASr. VP of Fin.100kN/A1961
Mr. Milton Charles Ault IIIFounder & Chairman EmeritusN/AN/A1970
Ms. Lien T. EscalonaChief Financial OfficerN/AN/A1969
Mr. David J. KatzoffChief Operating OfficerN/AN/A1962
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.

Corporate governance

Alzamend Neuro, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.